|

Entrectinib Clinical Trials

10 actively recruiting trials across 2 locations

No change since May 2026

Also known as: RO7102122, Rozlytrek, Rozlytrek®; RXDX-101

Pipeline

Phase 2: 5Phase 3: 1Phase 2/3: 2

Top Sponsors

  • Cancer Research UK2
  • West China Hospital1
  • The Netherlands Cancer Institute1
  • St. Jude Children's Research Hospital1
  • Seoul National University Bundang Hospital1

Indications

Other8 trials

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Phase 2/3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Phase 2/3
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Study on the Mechanism of Acquired Resistance of Entrectinib
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Duarte, California1 trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2

Memphis, Tennessee1 trial

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.